029 Group SE

Earnings Release • Aug 24, 2004

News Details

Ad-hoc | 24 August 2004 07:53

Rhein Biotech N.V. reports 2004 Half Year results

Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Maastricht, August 24, 2004 Rhein Biotech N.V. reports for the Half Year 2004 net sales of 13.1 million Euro. The EBITDA was 1.7 million Euro, while the loss from operations (EBIT) was -2.9 million Euro. Rhein Biotech’s net loss in the Half Year 2004 was -2.5 million Euro. The company’s cash position at the end of June 2004 was 17.5 million Euro. Mainly due to the price pressure in the Hepatitis-B-vaccines market the net sales where 8% lower than in the same period of the previous year. Due to the positive development of the financial result the consolidated loss is significantly lower. Consolidated income statement for the half year ending June 30, 2004 (Dutch GAAP. The results are unaudited) Amounts in EUR ‘000. 2004 2003 Net sales 13’128 14’286 Loss from operations (EBIT) -2’863 -2’264 Financial result, net 53 -2’388 Other income 17 148 Loss before taxes -2’793 -4’504 Taxes-86-72 Minority interests 383 0 Consolidated net loss -2’496 -4’576 Income from operations before depreciation (EBITDA) 1’739 2’075 end of ad-hoc-announcement (c)DGAP 24.08.2004 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: Rhein Biotech is a member of the Berna Biotech Group, a leading player for innovation in vaccines. For further information Rhein Biotech N.V. Company Contact: Béatrice Keller Communication Manager E: investor.relations@bernabiotech.com ——————————————————————————– WKN: 919544; ISIN: NL0000230324; Index: Listed: Geregelter Markt in Frankfurt (General Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 240753 Aug 04